2-[(4-cyanophenyl)methyl]-1-oxo-N-(pyrimidin-5-ylmethyl)-3H-isoindole-5-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[(4-cyanophenyl)methyl]-1-oxo-N-(pyrimidin-5-ylmethyl)-3H-isoindole-5-carboxamide
• 化学式: C₂₂H₁₇N₅O₂
• 分子量: 383.4
• InChiKey: LDFBVOLKOZFLLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  99
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE PHTALIMIDE INHIBITEURS DE METALLOPROTEINASE DE MATRICE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014365A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, Y1, Y3, Y5, Y6, Y8, and RZ are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically' acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.